Elizabeth S. Klings MD
Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine
72 E. Concord Street | (617) 638-8679
Pulmonary, Allergy, Sleep & Critical Care Medicine
Center of Excellence in Sickle Cell Disease
Evans Center for Interdisciplinary Biomedical Research
Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.
Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.
Pulmonary, Allergy, Sleep & Critical Care Medicine Faculty
Boston Medical Center Provider Profile
MD, New York University School of Medicine, 1992
Biology, BA, New York University, 1988
Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 20. PMID: 36662449.Published on 1/6/2023
Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 06. PMID: 36607535.Published on 1/1/2023
Cohen RT, Klings ES. Systemic Steroids and the Risk of Vasoocclusive Events in Patients with Sickle Cell Disease. Ann Am Thorac Soc. 2023 Jan; 20(1):18-20. PMID: 36166277.Published on 10/1/2022
Gillmeyer KR, Rinne ST, Qian SX, Maron BA, Johnson SW, Klings ES, Wiener RS. Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension. Pulm Circ. 2022 Oct; 12(4):e12171. PMID: 36568691.Published on 10/1/2022
Sangani RA, Lui JK, Gillmeyer KR, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. Pulm Circ. 2022 Oct; 12(4):e12117. PMID: 36238967.Published on 7/1/2022
Johnson SW, Gillmeyer KR, Bolton RE, McCullough MB, Qian SX, Maron BA, Klings ES, Wiener RS. Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Ann Am Thorac Soc. 2022 Jul; 19(7):1236-1239. PMID: 35312466.Published on 6/9/2022
Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2022 Jun 09. PMID: 35678779.Published on 4/15/2022
Nakagawa A, Cooper MK, Kost-Alimova M, Berstler J, Yu B, Berra L, Klings ES, Huang MS, Heeney MM, Bloch DB, Zapol WM. High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells. ACS Omega. 2022 Apr 26; 7(16):14009-14016. PMID: 35559170.Published on 4/5/2022
Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2022 Jul; 74(7):1219-1226. PMID: 34085410.Published on 2/16/2022
Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Rev Hematol. 2022 Feb; 15(2):117-125. PMID: 35143368.
Published on 7/15/2022
Athletes gearing up for Boston Triathlon on July 24
Published on 4/20/2021
New Strategies Confront the Critical Need to Improve Sickle Cell Disease Care
Published on 3/3/2021
Doctors: Battling virus 'has definitely been challenging'
Published on 6/16/2020
Reducing Care Fragmentation in Sickle Cell DiseaseView full list of 4 media mentions.